Leading Pharma, LLC received FDA approval for generic oral Leucovorin Calcium, introducing a new entrant that is expected to intensify competition and exert downward pressure on pricing. This approval positions the company to capture market share from existing branded suppliers, potentially impacting the profitability of incumbents in this established therapeutic class.